Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors [4]

AIDS

Volumn 16, Issue 4, 2002, Pages 674-676

  Weiss, Johanna ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Haefeli, Walter Emil ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIMETHYL SULFOXIDE; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AQUEOUS SOLUTION; DRUG METABOLISM; DRUG SOLUBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LETTER; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS INHIBITION;

HIV PROTEASE INHIBITORS; INDINAVIR; ISOTONIC SOLUTIONS; RITONAVIR; SAQUINAVIR; SOLUBILITY;

EID: 0037040347     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203080-00024     Document Type: Letter

References (25)

1. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997
2. HIV-protease inhibitors
3. Interactions among drugs for HIV and opportunistic infections
4. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
5. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
6. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir
7. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
8. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir
9. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers
10. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs
11. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
12. Interaction of anti-HIV protease inhibitors with the multidrug transporter p-glycoprotein (P-gp) in human cultured cells
13. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins
14. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
15. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
16. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier
17. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: Study on combinations of two kinds of HIV-1 protease inhibitors
18. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
19. Saquinavir clinical pharmacology and efficacy
20. Preformulation studies of a novel protease inhibitor, AG1343
21. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
22. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport
23. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion
24. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoprotein
25. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4